Global Nucleic Acid Therapeutics CDMO Market Size Study, by Type (Gene Therapy, RNA-based Therapies), Service (Process Development and Optimization), End-use, Application, and Regional Forecasts 2022-2032

Description

The Global Nucleic Acid Therapeutics CDMO Market, valued at approximately USD 13.44 million in 2023, is expected to exhibit a robust growth trajectory, achieving a CAGR of 14.20% over the forecast period 2024-2032. This burgeoning market underscores the transformative role of Contract Development and Manufacturing Organizations (CDMOs) in revolutionizing the production and optimization of nucleic acid therapeutics. As the biotechnology sector embraces innovative gene and RNA-based therapies, the demand for specialized CDMO services is accelerating, reflecting the industry's shift towards precision medicine.

Advancements in nucleic acid-based therapeutics have unlocked groundbreaking possibilities for tackling genetic disorders, cancer, and rare diseases. The CDMO market is particularly buoyed by the rising demand for efficient process development and optimization services, which are pivotal in ensuring the scalability and regulatory compliance of these therapies. Significant investments in research and development have enabled the production of high-quality therapeutic solutions, thereby catalyzing market expansion. However, the high cost of development and manufacturing remains a notable challenge, though increasing automation and technological innovations are steadily mitigating these concerns.

Regionally, North America dominates the market landscape, owing to its established biotechnology ecosystem, strong funding pipelines, and a regulatory framework conducive to innovation. Europe closely follows, driven by a robust focus on advanced therapeutics and a growing number of CDMO partnerships. Meanwhile, the Asia Pacific region is emerging as a hotbed for growth, fueled by substantial investments in biotechnology, cost-effective manufacturing capabilities, and government initiatives promoting biopharmaceutical advancements. Latin America and the Middle East & Africa are poised to witness steady growth, propelled by improving healthcare infrastructure and expanding access to advanced therapeutics.

Major market players included in this report are:

Lonza Group AG
Catalent, Inc.
Thermo Fisher Scientific Inc.
Wuxi AppTec
Samsung Biologics
Charles River Laboratories
AGC Biologics
Jubilant Biosys
Cobra Biologics
Cytovance Biologics
Curia Global, Inc.
Sarepta Therapeutics
Takara Bio Inc.
Genezen
BioNTech SE

The detailed segments and sub-segments of the market are explained below:

By Type:

Gene Therapy
RNA-based Therapies

By Service:

Process Development and Optimization

By Application:

Rare Diseases
Oncology
Genetic Disorders
Others

By End-Use:

Biotechnology Companies
Pharmaceutical Companies
Academic and Research Institutes

By Region:

North America:

U.S.
Canada

Europe:

UK
Germany
France
Spain
Italy
Rest of Europe

Asia Pacific:

China
India
Japan
Australia
South Korea
Rest of Asia Pacific

Latin America:

Brazil
Mexico
Rest of Latin America

Middle East & Africa:

Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Market estimates and forecasts spanning 2022-2032.
Detailed segmentation analysis including type, service, application, and end-use.
Comprehensive regional insights with granular country-level data.
Profiles of leading players in the nucleic acid therapeutics CDMO space.
Analysis of market trends, opportunities, and challenges shaping the competitive landscape.

Chapter 1. Global Nucleic Acid Therapeutics CDMO Market Executive Summary

1.1. Global Nucleic Acid Therapeutics CDMO Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type
  - 1.3.1.1. Gene Therapy
  - 1.3.1.2. RNA-based Therapies
- 1.3.2. By Service
  - 1.3.2.1. Process Development and Optimization
- 1.3.3. By Application
  - 1.3.3.1. Rare Diseases
  - 1.3.3.2. Oncology
  - 1.3.3.3. Genetic Disorders
  - 1.3.3.4. Others
- 1.3.4. By End-Use
  - 1.3.4.1. Biotechnology Companies
  - 1.3.4.2. Pharmaceutical Companies
  - 1.3.4.3. Academic and Research Institutes
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Nucleic Acid Therapeutics CDMO Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Nucleic Acid Therapeutics CDMO Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Demand for Gene and RNA-based Therapies
- 3.1.2. Increasing Investments in Biotechnology R&D
- 3.1.3. Expansion of Precision Medicine Initiatives
3.2. Market Challenges
- 3.2.1. High Development and Manufacturing Costs
- 3.2.2. Complex Regulatory Compliance
3.3. Market Opportunities
- 3.3.1. Technological Innovations and Automation
- 3.3.2. Expansion into Emerging Markets
- 3.3.3. Strategic Partnerships and Collaborations

Chapter 4. Global Nucleic Acid Therapeutics CDMO Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Nucleic Acid Therapeutics CDMO Market Size & Forecasts by Type 2022-2032

5.1. Segment Dashboard
5.2. Global Nucleic Acid Therapeutics CDMO Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Gene Therapy
- 5.2.2. RNA-based Therapies

Chapter 6. Global Nucleic Acid Therapeutics CDMO Market Size & Forecasts by Service 2022-2032

6.1. Segment Dashboard
6.2. Global Nucleic Acid Therapeutics CDMO Market: Service Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Process Development and Optimization

Chapter 7. Global Nucleic Acid Therapeutics CDMO Market Size & Forecasts by Application 2022-2032

7.1. Segment Dashboard
7.2. Global Nucleic Acid Therapeutics CDMO Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 7.2.1. Rare Diseases
- 7.2.2. Oncology
- 7.2.3. Genetic Disorders
- 7.2.4. Others

Chapter 8. Global Nucleic Acid Therapeutics CDMO Market Size & Forecasts by End-Use 2022-2032

8.1. Segment Dashboard
8.2. Global Nucleic Acid Therapeutics CDMO Market: End-Use Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 8.2.1. Biotechnology Companies
- 8.2.2. Pharmaceutical Companies
- 8.2.3. Academic and Research Institutes

Chapter 9. Global Nucleic Acid Therapeutics CDMO Market Size & Forecasts by Region 2022-2032

9.1. North America Nucleic Acid Therapeutics CDMO Market
- 9.1.1. U.S. Nucleic Acid Therapeutics CDMO Market
  - 9.1.1.1. Type Breakdown Size & Forecasts, 2022-2032
  - 9.1.1.2. End-Use Breakdown Size & Forecasts, 2022-2032
- 9.1.2. Canada Nucleic Acid Therapeutics CDMO Market
9.2. Europe Nucleic Acid Therapeutics CDMO Market
- 9.2.1. UK Nucleic Acid Therapeutics CDMO Market
- 9.2.2. Germany Nucleic Acid Therapeutics CDMO Market
- 9.2.3. France Nucleic Acid Therapeutics CDMO Market
- 9.2.4. Spain Nucleic Acid Therapeutics CDMO Market
- 9.2.5. Italy Nucleic Acid Therapeutics CDMO Market
- 9.2.6. Rest of Europe Nucleic Acid Therapeutics CDMO Market
9.3. Asia-Pacific Nucleic Acid Therapeutics CDMO Market
- 9.3.1. China Nucleic Acid Therapeutics CDMO Market
- 9.3.2. India Nucleic Acid Therapeutics CDMO Market
- 9.3.3. Japan Nucleic Acid Therapeutics CDMO Market
- 9.3.4. Australia Nucleic Acid Therapeutics CDMO Market
- 9.3.5. South Korea Nucleic Acid Therapeutics CDMO Market
- 9.3.6. Rest of Asia Pacific Nucleic Acid Therapeutics CDMO Market
9.4. Latin America Nucleic Acid Therapeutics CDMO Market
- 9.4.1. Brazil Nucleic Acid Therapeutics CDMO Market
- 9.4.2. Mexico Nucleic Acid Therapeutics CDMO Market
- 9.4.3. Rest of Latin America Nucleic Acid Therapeutics CDMO Market
9.5. Middle East & Africa Nucleic Acid Therapeutics CDMO Market
- 9.5.1. Saudi Arabia Nucleic Acid Therapeutics CDMO Market
- 9.5.2. South Africa Nucleic Acid Therapeutics CDMO Market
- 9.5.3. Rest of Middle East & Africa Nucleic Acid Therapeutics CDMO Market

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
- 10.1.1. Lonza Group AG
- 10.1.2. Catalent, Inc.
- 10.1.3. Thermo Fisher Scientific Inc.
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Lonza Group AG
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Catalent, Inc.
- 10.3.3. Thermo Fisher Scientific Inc.
- 10.3.4. Wuxi AppTec
- 10.3.5. Samsung Biologics
- 10.3.6. Charles River Laboratories
- 10.3.7. AGC Biologics
- 10.3.8. Jubilant Biosys
- 10.3.9. Cobra Biologics
- 10.3.10. Cytovance Biologics

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes